Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MATULANE vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Matulane (procarbazine) is a prodrug that undergoes metabolic activation to generate cytotoxic alkylating metabolites. It inhibits DNA, RNA, and protein synthesis through methylation of nucleic acids and proteins, and may also inhibit monoamine oxidase.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Treatment of advanced Hodgkin lymphoma (in combination with other drugs),Treatment of non-Hodgkin lymphoma (off-label),Treatment of brain tumors (off-label)
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
200-300 mg orally once daily for 10-14 days as part of MOPP regimen; maintenance dose: 50-100 mg orally once daily after hematologic recovery.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life is approximately 7-10 hours (range 5-15 hours) in adults; context: prolonged in hepatic or renal impairment.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Procarbazine is metabolized primarily by the liver via oxidation by CYP450 enzymes and other oxidases to active metabolites. It also undergoes some metabolism by monoamine oxidase (MAO) in the liver and other tissues.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Primarily renal (approximately 50-60% as unchanged drug and metabolites) and fecal (approximately 10-20%); minor biliary excretion.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Approximately 10-20% bound to plasma proteins (mainly albumin); minimal binding.
82–88% bound to plasma proteins (primarily albumin).
Approximately 3-4 L/kg; indicates extensive tissue distribution including brain (penetrates CNS).
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Oral bioavailability is nearly complete (close to 100%) after oral administration.
Oral: 65–80% (median 73%)
GFR ≥50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose to 50-75%; GFR <10 m L/min: avoid use or reduce to 50% and monitor.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh A: 100% of dose; Child-Pugh B: reduce by 50%; Child-Pugh C: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Based on BSA: 100 mg/m2 orally once daily for 14 days as part of MOPP; or 50 mg/m2 orally on days 1-14.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
Start at lower end of dosing range (e.g., 200 mg daily) due to increased risk of myelosuppression and renal/hepatic impairment; monitor CBCs closely.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
Procarbazine is carcinogenic, mutagenic, and teratogenic. It should be used only by physicians experienced in cancer chemotherapy. Patients receiving procarbazine should be carefully monitored for hematologic toxicity.
None
Bone marrow suppression (leukopenia, thrombocytopenia, anemia) requires dose adjustment; discontinue if toxicity is severe. CNS effects (drowsiness, depression, confusion) may occur. Disulfiram-like reaction with alcohol. Hypertensive crisis can occur with tyramine-rich foods or sympathomimetics due to MAO inhibition. Monitor for secondary malignancies. Fetal harm can occur; avoid pregnancy.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Hypersensitivity to procarbazine; concomitant use with MAO inhibitors, tricyclic antidepressants, or other drugs with MAO-inhibiting activity; severe bone marrow depression; pregnancy.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Avoid tyramine-rich foods: aged cheeses (cheddar, Swiss), cured meats (salami, pepperoni), fermented soy products (tofu, miso), sauerkraut, pickled herring, broad bean pods, yeast extracts, red wine, beer, and draft beers. Also avoid alcohol completely due to additive CNS depression.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Matulane (procarbazine) is a known teratogen. First trimester exposure is associated with major congenital malformations. Second and third trimester exposure carries risk of intrauterine growth restriction, fetal bone marrow suppression, and potential carcinogenesis. Use contraindicated in pregnancy.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Procarbazine is excreted into breast milk. M/P ratio not reported. Due to potential for carcinogenicity and adverse effects in the nursing infant, breastfeeding is contraindicated during matulane therapy and for at least 2 weeks after last dose.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No well-established safe dose in pregnancy. If therapy is deemed essential despite risks, significant dose reduction and increased monitoring advised. Pharmacokinetic changes in pregnancy may alter procarbazine metabolism, but specific dose adjustments are not defined. Use only in life-threatening conditions with expert consultation.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Matulane (procarbazine) is a monoamine oxidase inhibitor (MAOI); concurrent use with sympathomimetics, tyramine-rich foods, or tricyclic antidepressants can precipitate hypertensive crisis. It is also a potent CNS depressant; avoid alcohol. Monitor for leukopenia and thrombocytopenia; nadir typically occurs 2-4 weeks after therapy. Discontinue if hypersensitivity pneumonitis occurs.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Avoid foods high in tyramine such as aged cheeses, cured meats, fermented foods, and alcoholic beverages (especially beer and red wine) to prevent severe high blood pressure.,Do not take any over-the-counter medications, especially cold, sinus, or allergy medications, without consulting your doctor due to risk of drug interactions.,This drug may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, or shortness of breath immediately.,Use effective contraception during treatment and for at least 1 month after stopping, as this drug can harm an unborn baby.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MATULANE vs AGRYLIN, answered by our medical review team.
MATULANE is a Antineoplastic Agent that works by Matulane (procarbazine) is a prodrug that undergoes metabolic activation to generate cytotoxic alkylating metabolites. It inhibits DNA, RNA, and protein synthesis through methylation of nucleic acids and proteins, and may also inhibit monoamine oxidase.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MATULANE and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MATULANE is: 200-300 mg orally once daily for 10-14 days as part of MOPP regimen; maintenance dose: 50-100 mg orally once daily after hematologic recovery.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MATULANE and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MATULANE is classified as Category C. Matulane (procarbazine) is a known teratogen. First trimester exposure is associated with major congenital malformations. Second and third trimester exposure carries risk of intrau. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.